6617-04-5

Basic information

• Product Name: 3-{4-[(4-chlorophenyl)sulfanyl]-3-nitrophenyl}-2-cyano-N-(4-methoxyphenyl)prop-2-enamide
• CAS NO: 6617-04-5
• Molecular Formula: C₉H₁₆O₂
• Molecular Weight: 465.9088
• Mol File: 6617-04-5.mol

Chemical Properties

• Boiling Point: 698.5°C at 760 mmHg
• Flash Point: 376.3°C
• Density: 1.43g/cm³
• Vapor Pressure: 2.32E-19mmHg at 25°C
• Refractive Index: 1.687
• CAS DataBase Reference: 3-{4-[(4-chlorophenyl)sulfanyl]-3-nitrophenyl}-2-cyano-N-(4-methoxyphenyl)prop-2-enamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-{4-[(4-chlorophenyl)sulfanyl]-3-nitrophenyl}-2-cyano-N-(4-methoxyphenyl)prop-2-enamide(6617-04-5)
• EPA Substance Registry System: 3-{4-[(4-chlorophenyl)sulfanyl]-3-nitrophenyl}-2-cyano-N-(4-methoxyphenyl)prop-2-enamide(6617-04-5)

Safety Data

• Hazardous Substances Data: 6617-04-5(Hazardous Substances Data)

Upstream product

• 846056-26-6 (2-methyl-cyclohexyl)-acetone 
• 116530-83-7 2-Ethylmethylcyclohexaneacetate 
• 13373-66-5 1-Methyl-2-oxabicyclo<3.3.0^1,5>nonan-3-one 
• 40599-78-8 trans-cyclohexane-1,2-diacetic acid 
• 64-18-6 formic acid 
• 2808-75-5 2-methyl-1-methylenecyclohexane 
• 591-49-1 1-methylcyclohex-1-ene 
• 3813-70-5 trans-2-methyl-1-(tosyloxy)cyclohexane 
• 53154-06-6 (+/-)--acetonitril 
• 108667-30-7 (+/-)-(cis-2-methyl-cyclohexyl)-malonic acid diethyl ester 
• 41976-96-9 (2-methyl-1-cyclohexenyl)propan-2-one 
• 27801-76-9 (2-methyl-cyclohexyliden)-acetic acid ethyl ester 
• 583-60-8 2-Methylcyclohexanone 
• 2209-00-9 Ethyl 2-methylcyclohexylideneacetate 

Downstream Products

• 90949-40-9 (+/-)-(cis-2-methyl-cyclohexyl)-acetic acid amide 
• 873398-10-8 1-(2-methyl-cyclohexylmethyl)-4,9-dihydro-3H-β-carboline 
• 111710-90-8 methyl 2-methylcyclohexylacetate 
• 860359-63-3 (2-methyl-cyclohexyl)-acetic acid-(2-indol-3-yl-ethylamide) 

Relevant articles and documents

Cycloalkylamides and their therapeutic applications

The present invention relates to the use of compounds of formula (I) for the treatment of a variety of disorders including, but not limited to, epilepsy, bipolar disorder, psychiatric disorders, migraine, pain, neuroprotection, and movement disorders.

Cycloalkylamides and their therapeutic applications

The present invention relates to the use of compounds of formula (I) for the treatment of a variety of disorders including, but not limited to, epilepsy, bipolar disorder, psychiatric disorders, migraine, pain, neuroprotection, and movement disorders.

Electron transfer induced reductive cleavage of γ-lactones to carboxylic acids by sodium-hexamethylphosphoric triamide (HMPA)

Sodium-hexamethylphosphoric triamide (HMPA) mediated electron transfer induced reductive cleavage of 1 -> 3 and 1 -> 2 γ-lactones fused in cyclohexane ring gives the corresponding carboxylic acids in good yields.

SYNTHESIS OF CYCLOHEXYLALIPHATIC ACIDS AND THEIR PHARMACOLOGICAL PROPERTIES

A series of substituted cyclohexylacetic acids I has been obtained by hydrogenation of the unsaturated analogues II and III.Esters of these analogues were prepared by the Horner-Wittig reaction of the corresponding cyclohexanones IV and/or 2-cyclohexenones V with triethyl phosphonoacetate.These esters were obtained in two isomeric forms (Z and E), differing in the double bond in the exo-position.The derivatives with a substituent in the 2-position exhibited a partial shift of the double bond to the cyclohexane ring; this shift was especially marked in the 2-phenyl derivative.With the acids I-III, activation of fibrinolysis was assessed by the hanging clot method; the anti-inflammatory effect was assessed by inhibition of two experimental model inflammations.The regression equation relating fibrinolytic capacity to lipophilicity was a quadratic one, the logarithm of optimum lipophilicity being log Popt = 5.55.A qualitative assessment of the anti-inflammatory effect in relation to lipophilicity suggests that log Popt is probably higher than with arylaliphatic acids.These acids seem to have an active site different from that of the acids I-III.